Study: Combo therapy cuts death risk from cryptococcal meningitis

04/4/2013 | HealthDay News

A treatment regimen that combines the antifungal drugs amphotericin B and flucytosine can lower cryptococcal meningitis patients' risk of death by 40% compared to amphotericin B alone, a study in the New England Journal of Medicine showed. Survivors also had lower odds of disability if they were treated with flucytosine, the researchers found.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC